UA125511C2 - Фармацевтична композиція, що містить бета-блокатор, інгібітор перетворення ферменту та протигіпертонічний засіб або нпзп - Google Patents

Фармацевтична композиція, що містить бета-блокатор, інгібітор перетворення ферменту та протигіпертонічний засіб або нпзп Download PDF

Info

Publication number: UA125511C2
Authority: UA; Ukraine
Prior art keywords: perindopril; bisoprolol; pharmaceutical composition; pharmaceutically acceptable; amlodipine
Prior art date: 2016-04-20

Application number

UAA201811111A

Other languages

English (en)

Ukrainian (uk)

Inventor

Жіль Фонкнехтен

Жиль Фонкнехтен

Original Assignee

Ле Лаборатуар Сервьє

Ле Лаборатуар Сервье

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-04-20

Filing date

2017-04-19

Publication date

2022-04-13

2017-04-19 Application filed by Ле Лаборатуар Сервьє, Ле Лаборатуар Сервье filed Critical Ле Лаборатуар Сервьє

2022-04-13 Publication of UA125511C2 publication Critical patent/UA125511C2/uk

Links

239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 50
239000002876 beta blocker Substances 0.000 title abstract description 20
229940097320 beta blocking agent Drugs 0.000 title abstract description 20
206010020772 Hypertension Diseases 0.000 title abstract description 17
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 title description 11
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 title description 11
239000003112 inhibitor Substances 0.000 title description 7
102000004190 Enzymes Human genes 0.000 title description 4
108090000790 Enzymes Proteins 0.000 title description 4
229960002582 perindopril Drugs 0.000 claims abstract description 74
IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 claims abstract description 71
229960002781 bisoprolol Drugs 0.000 claims abstract description 61
VHYCDWMUTMEGQY-UHFFFAOYSA-N bisoprolol Chemical compound CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VHYCDWMUTMEGQY-UHFFFAOYSA-N 0.000 claims abstract description 56
238000011282 treatment Methods 0.000 claims abstract description 39
208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 20
208000029078 coronary artery disease Diseases 0.000 claims abstract description 16
230000002265 prevention Effects 0.000 claims abstract description 15
ZPBWCRDSRKPIDG-UHFFFAOYSA-N amlodipine benzenesulfonate Chemical compound OS(=O)(=O)C1=CC=CC=C1.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl ZPBWCRDSRKPIDG-UHFFFAOYSA-N 0.000 claims description 37
229960001138 acetylsalicylic acid Drugs 0.000 claims description 34
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 30
229960004569 indapamide Drugs 0.000 claims description 30
150000003839 salts Chemical class 0.000 claims description 30
229960000528 amlodipine Drugs 0.000 claims description 28
NDDAHWYSQHTHNT-UHFFFAOYSA-N indapamide Chemical compound CC1CC2=CC=CC=C2N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 NDDAHWYSQHTHNT-UHFFFAOYSA-N 0.000 claims description 26
229960005400 bisoprolol fumarate Drugs 0.000 claims description 22
239000002775 capsule Substances 0.000 claims description 21
RZPZLFIUFMNCLY-WLHGVMLRSA-N (e)-but-2-enedioic acid;1-(propan-2-ylamino)-3-[4-(2-propan-2-yloxyethoxymethyl)phenoxy]propan-2-ol Chemical compound OC(=O)\C=C\C(O)=O.CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 RZPZLFIUFMNCLY-WLHGVMLRSA-N 0.000 claims description 20
229960003076 perindopril arginine Drugs 0.000 claims description 20
RYCSJJXKEWBUTI-YDYAIEMNSA-N perindopril arginine Chemical compound OC(=O)[C@@H](N)CCCNC(N)=N.C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 RYCSJJXKEWBUTI-YDYAIEMNSA-N 0.000 claims description 19
229960004005 amlodipine besylate Drugs 0.000 claims description 14
208000037849 arterial hypertension Diseases 0.000 claims description 13
239000000546 pharmaceutical excipient Substances 0.000 claims description 6
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
-1 salts salt Chemical class 0.000 claims description 3
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 2
IYNMDWMQHSMDDE-MHXJNQAMSA-N perindopril erbumine Chemical compound CC(C)(C)N.C1CCC[C@@H]2N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H](C(O)=O)C[C@@H]21 IYNMDWMQHSMDDE-MHXJNQAMSA-N 0.000 claims 1
239000000203 mixture Substances 0.000 abstract description 23
239000003814 drug Substances 0.000 abstract description 17
229940124597 therapeutic agent Drugs 0.000 abstract description 14
229940030600 antihypertensive agent Drugs 0.000 abstract description 6
239000002220 antihypertensive agent Substances 0.000 abstract description 6
239000004480 active ingredient Substances 0.000 description 28
239000003826 tablet Substances 0.000 description 26
150000004677 hydrates Chemical class 0.000 description 15
239000012729 immediate-release (IR) formulation Substances 0.000 description 12
230000034994 death Effects 0.000 description 11
231100000517 death Toxicity 0.000 description 11
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 9
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 9
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 9
239000002356 single layer Substances 0.000 description 9
229960003943 hypromellose Drugs 0.000 description 8
238000000034 method Methods 0.000 description 8
229940014002 perindopril and amlodipine Drugs 0.000 description 8
239000004475 Arginine Substances 0.000 description 7
239000002253 acid Substances 0.000 description 7
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 7
235000010980 cellulose Nutrition 0.000 description 7
229920002678 cellulose Polymers 0.000 description 7
239000001913 cellulose Substances 0.000 description 7
239000002934 diuretic Substances 0.000 description 7
239000012535 impurity Substances 0.000 description 7
208000010125 myocardial infarction Diseases 0.000 description 7
239000005541 ACE inhibitor Substances 0.000 description 6
108090000312 Calcium Channels Proteins 0.000 description 6
102000003922 Calcium Channels Human genes 0.000 description 6
206010019280 Heart failures Diseases 0.000 description 6
229920000168 Microcrystalline cellulose Polymers 0.000 description 6
235000019813 microcrystalline cellulose Nutrition 0.000 description 6
239000008108 microcrystalline cellulose Substances 0.000 description 6
229940016286 microcrystalline cellulose Drugs 0.000 description 6
238000002360 preparation method Methods 0.000 description 6
239000000725 suspension Substances 0.000 description 6
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 5
229940125400 channel inhibitor Drugs 0.000 description 5
239000007941 film coated tablet Substances 0.000 description 5
230000003993 interaction Effects 0.000 description 5
208000031225 myocardial ischemia Diseases 0.000 description 5
229940015112 perindopril and bisoprolol Drugs 0.000 description 5
239000008213 purified water Substances 0.000 description 5
239000000454 talc Substances 0.000 description 5
235000012222 talc Nutrition 0.000 description 5
229910052623 talc Inorganic materials 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 4
230000007170 pathology Effects 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
206010002383 Angina Pectoris Diseases 0.000 description 3
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
230000008901 benefit Effects 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
238000007907 direct compression Methods 0.000 description 3
230000001882 diuretic effect Effects 0.000 description 3
229940079593 drug Drugs 0.000 description 3
230000002526 effect on cardiovascular system Effects 0.000 description 3
239000000945 filler Substances 0.000 description 3
239000001863 hydroxypropyl cellulose Substances 0.000 description 3
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
230000000302 ischemic effect Effects 0.000 description 3
229940126601 medicinal product Drugs 0.000 description 3
238000010197 meta-analysis Methods 0.000 description 3
239000000843 powder Substances 0.000 description 3
YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical group CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 3
METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 2
102000005862 Angiotensin II Human genes 0.000 description 2
101800000733 Angiotensin-2 Proteins 0.000 description 2
BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 2
102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
108091000080 Phosphotransferase Proteins 0.000 description 2
208000007718 Stable Angina Diseases 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
230000009471 action Effects 0.000 description 2
239000008186 active pharmaceutical agent Substances 0.000 description 2
229950006323 angiotensin ii Drugs 0.000 description 2
150000001483 arginine derivatives Chemical class 0.000 description 2
229960002274 atenolol Drugs 0.000 description 2
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
229910001424 calcium ion Inorganic materials 0.000 description 2
230000000747 cardiac effect Effects 0.000 description 2
229940097217 cardiac glycoside Drugs 0.000 description 2
239000002368 cardiac glycoside Substances 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
238000002648 combination therapy Methods 0.000 description 2
230000000295 complement effect Effects 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
229920001577 copolymer Polymers 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
238000011161 development Methods 0.000 description 2
206010012601 diabetes mellitus Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
229940030606 diuretics Drugs 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
239000008187 granular material Substances 0.000 description 2
230000036541 health Effects 0.000 description 2
208000019622 heart disease Diseases 0.000 description 2
230000001771 impaired effect Effects 0.000 description 2
239000010410 layer Substances 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
230000008520 organization Effects 0.000 description 2
102000020233 phosphotransferase Human genes 0.000 description 2
229920000333 poly(propyleneimine) Polymers 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
230000009467 reduction Effects 0.000 description 2
230000000250 revascularization Effects 0.000 description 2
239000002904 solvent Substances 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000007858 starting material Substances 0.000 description 2
229930002534 steroid glycoside Natural products 0.000 description 2
150000008143 steroidal glycosides Chemical class 0.000 description 2
208000019270 symptomatic heart failure Diseases 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
230000002861 ventricular Effects 0.000 description 2
KOHIRBRYDXPAMZ-YHBROIRLSA-N (S,R,R,R)-nebivolol Chemical compound C1CC2=CC(F)=CC=C2O[C@H]1[C@H](O)CNC[C@@H](O)[C@H]1OC2=CC=C(F)C=C2CC1 KOHIRBRYDXPAMZ-YHBROIRLSA-N 0.000 description 1
YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 1
UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
229940086440 Angiotensin I converting enzyme inhibitor Drugs 0.000 description 1
101800000734 Angiotensin-1 Proteins 0.000 description 1
102400000344 Angiotensin-1 Human genes 0.000 description 1
108010064733 Angiotensins Proteins 0.000 description 1
102000015427 Angiotensins Human genes 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
206010003658 Atrial Fibrillation Diseases 0.000 description 1
102400000967 Bradykinin Human genes 0.000 description 1
101800004538 Bradykinin Proteins 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
206010007558 Cardiac failure chronic Diseases 0.000 description 1
JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
208000017667 Chronic Disease Diseases 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
208000005189 Embolism Diseases 0.000 description 1
239000004593 Epoxy Substances 0.000 description 1
208000007530 Essential hypertension Diseases 0.000 description 1
102000018389 Exopeptidases Human genes 0.000 description 1
108010091443 Exopeptidases Proteins 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
241000725303 Human immunodeficiency virus Species 0.000 description 1
208000035150 Hypercholesterolemia Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
201000001068 Prinzmetal angina Diseases 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
206010057362 Underdose Diseases 0.000 description 1
208000007814 Unstable Angina Diseases 0.000 description 1
239000002250 absorbent Substances 0.000 description 1
230000002745 absorbent Effects 0.000 description 1
229960002122 acebutolol Drugs 0.000 description 1
GOEMGAFJFRBGGG-UHFFFAOYSA-N acebutolol Chemical compound CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(C(C)=O)=C1 GOEMGAFJFRBGGG-UHFFFAOYSA-N 0.000 description 1
230000021736 acetylation Effects 0.000 description 1
238000006640 acetylation reaction Methods 0.000 description 1
239000012190 activator Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000008272 agar Substances 0.000 description 1
235000010419 agar Nutrition 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
229940009868 aluminum magnesium silicate Drugs 0.000 description 1
WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 1
ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 1
125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
238000013475 authorization Methods 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
159000000007 calcium salts Chemical class 0.000 description 1
239000007963 capsule composition Substances 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
239000000969 carrier Substances 0.000 description 1
206010008118 cerebral infarction Diseases 0.000 description 1
208000026106 cerebrovascular disease Diseases 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
229940075614 colloidal silicon dioxide Drugs 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
229940099112 cornstarch Drugs 0.000 description 1
239000007857 degradation product Substances 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
201000010099 disease Diseases 0.000 description 1
230000006806 disease prevention Effects 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000000975 dye Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
239000012467 final product Substances 0.000 description 1
238000009093 first-line therapy Methods 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
229940014259 gelatin Drugs 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
229960002003 hydrochlorothiazide Drugs 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
239000007943 implant Substances 0.000 description 1
230000006872 improvement Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
238000011221 initial treatment Methods 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
238000009434 installation Methods 0.000 description 1
229960003825 ivabradine Drugs 0.000 description 1
ACRHBAYQBXXRTO-OAQYLSRUSA-N ivabradine Chemical compound C1CC2=CC(OC)=C(OC)C=C2CC(=O)N1CCCN(C)C[C@H]1CC2=C1C=C(OC)C(OC)=C2 ACRHBAYQBXXRTO-OAQYLSRUSA-N 0.000 description 1
239000008101 lactose Substances 0.000 description 1
238000012153 long-term therapy Methods 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
238000011418 maintenance treatment Methods 0.000 description 1
150000002688 maleic acid derivatives Chemical class 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
229960002237 metoprolol Drugs 0.000 description 1
IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
239000011707 mineral Substances 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
238000002156 mixing Methods 0.000 description 1
210000002464 muscle smooth vascular Anatomy 0.000 description 1
210000004165 myocardium Anatomy 0.000 description 1
229960000619 nebivolol Drugs 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
230000037361 pathway Effects 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
239000006187 pill Substances 0.000 description 1
230000010118 platelet activation Effects 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
230000002028 premature Effects 0.000 description 1
238000003825 pressing Methods 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
230000008569 process Effects 0.000 description 1
239000000047 product Substances 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
238000009256 replacement therapy Methods 0.000 description 1
230000033764 rhythmic process Effects 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
238000009097 single-agent therapy Methods 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
229940045902 sodium stearyl fumarate Drugs 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
239000007921 spray Substances 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
229940032147 starch Drugs 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
229940124530 sulfonamide Drugs 0.000 description 1
150000003456 sulfonamides Chemical class 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
230000001975 sympathomimetic effect Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000008685 targeting Effects 0.000 description 1
238000012360 testing method Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
239000003451 thiazide diuretic agent Substances 0.000 description 1
DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
230000009466 transformation Effects 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
239000001069 triethyl citrate Substances 0.000 description 1
VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
235000013769 triethyl citrate Nutrition 0.000 description 1
201000008827 tuberculosis Diseases 0.000 description 1
230000002792 vascular Effects 0.000 description 1
239000005526 vasoconstrictor agent Substances 0.000 description 1
230000000304 vasodilatating effect Effects 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
238000005550 wet granulation Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Heart & Thoracic Surgery (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

UAA201811111A 2016-04-20 2017-04-19 Фармацевтична композиція, що містить бета-блокатор, інгібітор перетворення ферменту та протигіпертонічний засіб або нпзп UA125511C2 (uk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR1653502A FR3050380B1 (fr)	2016-04-20	2016-04-20	Composition pharmaceutique comprenant un betabloquant, un inhibiteur de l'enzyme de conversion et un antihypertenseur ou un ains.
PCT/FR2017/050929 WO2017182754A1 (fr)	2016-04-20	2017-04-19	Composition pharmaceutique comprenant un betabloquant, un inhibiteur de l'enzyme de conversion et un antihypertenseur ou un ains

Publications (1)

Publication Number	Publication Date
UA125511C2 true UA125511C2 (uk)	2022-04-13

Family

ID=56943614

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UAA201811111A UA125511C2 (uk)	2016-04-20	2017-04-19	Фармацевтична композиція, що містить бета-блокатор, інгібітор перетворення ферменту та протигіпертонічний засіб або нпзп

Country Status (15)

Country	Link
EP (1)	EP3445342A1 (fr)
KR (1)	KR102267965B1 (fr)
CN (1)	CN109069438A (fr)
BR (1)	BR112018070968A2 (fr)
EA (1)	EA201892354A1 (fr)
FR (1)	FR3050380B1 (fr)
GE (2)	GEP20217310B (fr)
MA (1)	MA44728A (fr)
MX (1)	MX389586B (fr)
PH (1)	PH12018502155B1 (fr)
RU (1)	RU2756320C2 (fr)
SG (2)	SG11201808848SA (fr)
TN (1)	TN2018000344A1 (fr)
UA (1)	UA125511C2 (fr)
WO (1)	WO2017182754A1 (fr)

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2645710C2 (de)	1976-10-09	1985-06-27	Merck Patent Gmbh, 6100 Darmstadt	Phenoxy-amino-propanole, Verfahren zu ihrer Herstellung und pharmazeutische Zubereitung
FR2503155A2 (fr)	1980-10-02	1982-10-08	Science Union & Cie	Nouveaux imino diacides substitues, leurs procedes de preparation et leur emploi comme inhibiteur d'enzyme
FR2620709B1 (fr)	1987-09-17	1990-09-07	Adir	Procede de synthese industrielle du perindopril et de ses principaux intermediaires de synthese
FR2807431B1 (fr)	2000-04-06	2002-07-19	Adir	Nouveau procede de synthese du perindopril et de ses sels pharmaceutiquement acceptables
GB2361185A (en) *	2000-04-10	2001-10-17	Nicholas J Wald	Pharmaceutical formulation for the prevention of cardiovascular disease
AR036187A1 (es)	2001-07-24	2004-08-18	Adir	Un proceso para la preparacion de perindopril, compuestos analogos y sus sales, compuesto intermediario 2,5-dioxo-oxazolidina y proceso para preparar un intermediario
FR2827860B1 (fr)	2001-07-24	2004-12-10	Servier Lab	Nouveau procede de synthese de derives de l'acide (2s, 3as, 7as)-1-[(s)-alanyl]-octahydro-1h-indole-2-carboxyline et application a la synthese du perindopril
ATE365714T1 (de)	2002-01-30	2007-07-15	Servier Lab	Verfahren zur herstellung von hochreinem perindopril und zwischenverbindungen nützlich in der synthese
FR2838648B1 (fr)	2002-04-18	2004-05-21	Servier Lab	Nouveau sel de perindopril et les compositions pharmaceutiques qui le contiennent
ATE395913T1 (de)	2003-02-28	2008-06-15	Servier S A Lab	Verfahren zur herstellung von perindopril
DE60301930T2 (de)	2003-02-28	2006-07-27	Les Laboratoires Servier	Verfahren für die Synthese von Perindopril und seiner pharmazeutisch annehmbaren Salze
PT1321471E (pt)	2003-03-12	2005-07-29	Servier Lab	Novo processo de sintese do perindopril e dos seus sais aceitaveis sob o ponto de vista farmaceutico
SI1367061T1 (sl)	2003-06-30	2006-04-30	Servier Lab	Nov postopek za sintezo perindoprila in njegovih farmacevtsko sprejemljivih soli
SI1362864T1 (sl)	2003-06-30	2007-08-31	Servier Lab	Nov postopek za sintezo perindoprila in njegovih farmacevtsko sprejemljivih soli
EP1648422A4 (fr) *	2003-07-28	2007-09-19	Reddys Lab Inc Dr	Traitement et prevention d'accidents cardiovasculaires
DK1367062T3 (da)	2003-07-31	2007-01-02	Servier Lab	Ny fremgangsmåde til syntese af perindopril og farmaceutisk acceptable salte heraf
ES2271498T3 (es)	2003-07-31	2007-04-16	Les Laboratoires Servier	Nuevo procedimiento de sintesis de perindopril y de sus sales farmaceuticamente aceptables.
EP1380591B1 (fr)	2003-08-29	2005-11-16	Les Laboratoires Servier	Nouveau procédé de synthèse du perindopril et de ses sels pharmaceutiquement acceptables
ES2250853T3 (es)	2003-08-29	2006-04-16	Les Laboratoires Servier	Procedimiento para la sintesis de perindopril y de sus sales farmaceuticamente aceptables.
DE60308102T2 (de)	2003-08-29	2007-06-21	Les Laboratoires Servier	Verfahren für die Synthese von Perindopril und seiner pharmazeutisch annehmbaren Salzen
DE60311942T2 (de)	2003-11-19	2007-12-06	Les Laboratoires Servier	Verfahren für die Synthese von Perindopril und seiner pharmazeutischen annehmbaren Salzen
EP1422236B1 (fr)	2003-11-19	2007-02-14	Les Laboratoires Servier	Procédé de synthèse du perindopril et de ses sels pharmaceutiquement acceptables
SI1420029T1 (sl)	2003-12-10	2008-08-31	Servier Lab	Postopek za sintezo perindoprila in njegovih farmacevtsko sprejemljivih soli
SI21800A (sl)	2004-05-14	2005-12-31	Krka, Tovarna Zdravil, D.D., Novo Mesto	Nov postopek sinteze perindoprila
US20070116756A1 (en) *	2005-11-23	2007-05-24	Dr. Reddy's Laboratories Limited	Stable pharmaceutical compositions
FR2894825B1 (fr)	2005-12-21	2010-12-03	Servier Lab	Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion et les compositions pharmaceutiques qui la contiennent
FR2897866B1 (fr)	2006-02-28	2008-04-18	Servier Lab	Forme cristalline alpha du sel d'arginine du perindopril, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2897865B1 (fr)	2006-02-28	2008-04-18	Servier Lab	Forme cristalline beta du sel d'arginine du perindopril, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
CN101024082A (zh) *	2007-04-06	2007-08-29	张士东	一种全面预防和治疗心脑血管疾病复方药及其应用
AU2009263737B2 (en)	2008-06-24	2013-10-24	Tianish Laboratories Private Limited	Novel polymorphic forms of Perindopril (L)-Arginine and process for the preparation thereof
HU230877B1 (hu)	2008-09-30	2018-11-29	EGIS Gyógyszergyár NyR	Stabil kombinációs gyógyszerkészítmény
US9789187B2 (en) *	2009-02-11	2017-10-17	Cadila Pharmaceuticals Limited	Stable pharmaceutical composition for atherosclerosis
EP2424509A4 (fr) *	2009-04-30	2012-11-07	Reddys Lab Ltd Dr	Formulations de combinaison de médicament à dose fixe
FR2961105B1 (fr)	2010-06-15	2013-02-08	Servier Lab	Utilisation de l'association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion de l'angiotensine pour le traitement de l'insuffisance cardiaque
FR2985511B1 (fr)	2012-01-05	2014-01-03	Servier Lab	Forme cristalline delta du sel d'arginine du perindopril, son procede de preparation, et les compositions pharmaceutiques qui la contiennent

2016
- 2016-04-19 PH PH1/2018/502155A patent/PH12018502155B1/en unknown
- 2016-04-20 FR FR1653502A patent/FR3050380B1/fr not_active Expired - Fee Related
2017
- 2017-04-19 GE GEAP201714923A patent/GEP20217310B/en unknown
- 2017-04-19 CN CN201780023915.6A patent/CN109069438A/zh active Pending
- 2017-04-19 EA EA201892354A patent/EA201892354A1/ru unknown
- 2017-04-19 MX MX2018012790A patent/MX389586B/es unknown
- 2017-04-19 TN TNP/2018/000344A patent/TN2018000344A1/en unknown
- 2017-04-19 KR KR1020187033434A patent/KR102267965B1/ko not_active Expired - Fee Related
- 2017-04-19 BR BR112018070968A patent/BR112018070968A2/pt not_active Application Discontinuation
- 2017-04-19 GE GEAP202114923A patent/GEAP202114923A/en unknown
- 2017-04-19 RU RU2018140193A patent/RU2756320C2/ru active
- 2017-04-19 MA MA044728A patent/MA44728A/fr unknown
- 2017-04-19 SG SG11201808848SA patent/SG11201808848SA/en unknown
- 2017-04-19 UA UAA201811111A patent/UA125511C2/uk unknown
- 2017-04-19 WO PCT/FR2017/050929 patent/WO2017182754A1/fr not_active Ceased
- 2017-04-19 EP EP17722115.7A patent/EP3445342A1/fr not_active Withdrawn
- 2017-04-19 SG SG10202009894PA patent/SG10202009894PA/en unknown

Also Published As

Publication number	Publication date
SG11201808848SA (en)	2018-11-29
RU2018140193A3 (fr)	2020-06-03
PH12018502155B1 (en)	2024-03-27
PH12018502155A1 (en)	2019-07-15
FR3050380B1 (fr)	2020-07-10
FR3050380A1 (fr)	2017-10-27
MA44728A (fr)	2019-02-27
KR102267965B1 (ko)	2021-06-21
MX389586B (es)	2025-03-20
WO2017182754A1 (fr)	2017-10-26
GEAP202114923A (en)	2021-07-12
RU2018140193A (ru)	2020-05-20
KR20180132911A (ko)	2018-12-12
TN2018000344A1 (en)	2020-06-15
EA201892354A1 (ru)	2019-04-30
BR112018070968A2 (pt)	2019-01-29
RU2756320C2 (ru)	2021-09-29
CN109069438A (zh)	2018-12-21
EP3445342A1 (fr)	2019-02-27
SG10202009894PA (en)	2020-11-27
GEP20217310B (en)	2021-11-10

Publication	Publication Date	Title
JP3776931B2 (ja)	2006-05-24	Ａｃｅ阻害剤ラミプリルとジヒドロピリジン化合物を含有する新規医薬組成物
DK2273985T3 (en)	2016-04-25	Capsule for the prevention of cardiovascular diseases
SK284728B6 (sk)	2005-10-06	Farmaceutický prostriedok obsahujúci ibuprofen a domperidone na ošetrovanie migrény
KR101414814B1 (ko)	2014-07-21	염산레르카니디핀 및 발사르탄을 포함하는 복합 제제 및 이의 제조방법
Viskoper et al.	1997	A randomised, double-blind trial comparing mibefradil and amlodipine: two long-acting calcium antagonists with similar efficacy but different tolerability profiles
RU2750934C2 (ru)	2021-07-06	ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ИНГИБИТОР ГМГ-КоА РЕДУКТАЗЫ И ИНГИБИТОР АПФ
UA125511C2 (uk)	2022-04-13	Фармацевтична композиція, що містить бета-блокатор, інгібітор перетворення ферменту та протигіпертонічний засіб або нпзп
AU2010276461A1 (en)	2011-08-25	Pharmaceutical composition of levamlodipine or pharmaceutically acceptable salt thereof and beta receptor blocking agent, and use thereof
RU2702362C2 (ru)	2019-10-08	Фармацевтическая композиция, содержащая бета-блокатор и ингибитор ангиотензинпревращающего фермента
EP1465607B1 (fr)	2007-03-21	Compositions pharmaceutiques a liberation modifiee
US8470363B2 (en)	2013-06-25	Antihypertensive pharmaceutical composition
US20070099850A1 (en)	2007-05-03	Combination of acetylsalicylic acid and alpha-glucosidase inhibitors
CN101869562A (zh)	2010-10-27	左旋氨氯地平复方药物制剂
KR960008229B1 (ko)	1996-06-21	캡토프릴 서방성 정제 및 그의 제조방법
HK40082224A (en)	2023-06-02	Complex pharmaceutical preparation, for preventing or treating cardiovascular disease, comprising amlodipine, losartan and chlorthalidone in single-layer tablet
TW202214238A (zh)	2022-04-16	在單層片劑中包括氨氯地平、氯沙坦和氯噻酮的預防或治療心血管系統疾病的藥學上組合製劑
CN115666564A (zh)	2023-01-31	在单层片剂中包括氨氯地平、氯沙坦和氯噻酮的预防或治疗心血管系统疾病的药学上组合制剂
UA146315U (uk)	2021-02-10	Фармацевтична композиція
UA146758U (uk)	2021-03-17	Фармацевтична композиція
Roller et al.	2015	Disease state management: Cardiovascular conditions: Heart failure
TW201208676A (en)	2012-03-01	Use of dronedarone for the preparation of a medicament for the prevention of cardiovascular hospitalization or of mortality in patients with lone atrial fibrillation
KR20170113459A (ko)	2017-10-12	타다라필 및 암로디핀 함유 고형 복합제제